|
12 Apr 2019 |
89bio Announces Preclinical Data That Demonstrate Potential Utility of BIO89-100 for Treatment of NASH
|
|
09 Apr 2019 |
PhaseBio Announces Global License of PB1023 for the Treatment of Sarcopenia-Related Diseases to ImmunoForge
|
|
08 Apr 2019 |
Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
|
|
03 Apr 2019 |
Allergan and Molecular Partners Announce Topline Safety Results from MAPLE study of Abicipar pegol
|
|
03 Apr 2019 |
Sandoz resubmits biosimilar pegfilgrastim application to US FDA
|
|
30 Mar 2019 |
Selecta Biosciences Initiates Head-to-Head Clinical Trial (COMPARE) of SEL-212 vs. KRYSTEXXA® in Patients with Chronic Refractory Gout and Strengthens Management Team
|
|
26 Mar 2019 |
Promedior Received Breakthrough Therapy Designation from FDA for PRM-151 in Idiopathic Pulmonary Fibrosis
|
|
26 Mar 2019 |
Hansa Biopharma Receives Ethics and Regulatory Clearance to Start Phase 2 Study of Imlifidase in Acute Antibody Mediated Rejection in Kidney Transplantation
|
|
26 Mar 2019 |
Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019
|
|
26 Mar 2019 |
Therachon Presents Data from Preclinical and Phase I clinical Studies of Apraglutide for the Treatment of Short Bowel Syndrome at ASPEN 2019 Nutrition Science & Practice Conference
|
|
24 Mar 2019 |
Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data presented at ENDO
|
|
21 Mar 2019 |
OPKO Announces Positive Topline Results In Phase 2 Diabetes And Obesity Trial
|
|
21 Mar 2019 |
AB2 Bio Announces Readiness for Recruitment in Pivotal Phase 3 Trial of Tadekinig Alfa, a Novel Human Recombinant Interleukin-18 Binding Protein, in Children with Genetic Diagnosis of NLRC4-MAS Mutation or XIAP Deficiency, with Amended Design in the U.S.
|
|
20 Mar 2019 |
Arch Biopartners Receives Approval to Perform Phase I Clinical Trial for Metablok in Australia
|
|
20 Mar 2019 |
Novo Nordisk files oral semaglutide for US regulatory approval of glycaemic control, as well as for CV risk reduction for oral semaglutide and Ozempic
|
|
19 Mar 2019 |
Alkahest Doses First Subject in Phase 2 Clinical Trial of Lead Candidate in Patients with Severe Alzheimer's Disease
|
|
19 Mar 2019 |
Cytovation Initiates Clinical Development Programme With CyPep-1, a First-in-class Lytic Agent for Tumor Immunotherapy
|
|
19 Mar 2019 |
BioAegis Therapeutics Completes Enrollment in its Phase 1b/2a Dose-Ranging Safety Study of Recombinant Plasma Gelsolin for Community-Acquired Pneumonia
|
|
15 Mar 2019 |
Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia
|
|
15 Mar 2019 |
ImmunogenX Initiates Phase 2 Trial for its Lead Therapeutic and Diagnostic Candidates Latiglutenase and CypCel
|
|
15 Mar 2019 |
Spectrum Pharmaceuticals Provides BLA Filing Update for ROLONTIS® (eflapegrastim)
|
|
08 Mar 2019 |
FDA Accepts Supplemental Biologics License Applications (sBLAs) for BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Upper and Lower Limb Spasticity
|
|
07 Mar 2019 |
Baxter Announces U.S. FDA Approval and Launch of Ready-to-Use Cardiovascular Medicine Eptifibatide
|
|
06 Mar 2019 |
Zealand Pharma doses first patient in Phase 3 trial with dasiglucagon for the treatment of congenital hyperinsulinism
|
|
05 Mar 2019 |
I-Mab Biopharma Announces the Achievement of First Patient Dosing in Phase 1b/2a China Trial of TJ107 for Cancer and Chemotherapy-induced Lymphopenia
|
